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Abstract
In people with Type 2 diabetes, cardiovascular disease is a leading cause of morbidity and mortality. Thus, as well as
controlling glucose, reducing the risk of cardiovascular events is a key goal. The results of cardiovascular outcome trials
have led to updates for many national and international guidelines. England, Wales and Northern Ireland remain
exceptions, with the most recent update to the National Institute for Health and Care Excellence (NICE) guidelines
published in 2015. We reviewed current national and international guidelines and recommendations on the management
of people with Type 2 diabetes. This article shares our consensus on clinical recommendations for the use of sodium-
glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) in people with
Type 2 diabetes and established or at very high risk of cardiovascular disease in the UK. We also consider cost-
effectiveness for these therapies. We recommend considering each person’s cardiovascular risk and using diabetes
therapies with proven cardiovascular benefits when appropriate to improve long-term outcomes and cost-effectiveness.
Diabet. Med. 36, 1063–1071 (2019)
Introduction
The prevalence of Type 2 diabetes is rising rapidly in the UK
and across the world, in part due to the increasing prevalence
of obesity and the ageing population [1,2]. In people with
Type 2 diabetes, cardiovascular disease remains the leading
cause of morbidity and mortality [3]. Once cardiovascular
disease is present in a person with Type 2 diabetes, the risk of
all-cause mortality is increased threefold and the risk of
cardiovascular death is increased fivefold [4]. Thus, in
addition to controlling glucose, reducing the risk of cardio-
vascular events is a key goal in the management of people
with Type 2 diabetes. Before the establishment of cardiovas-
cular disease, treatment should aim to reduce the risk of
cardiovascular disease developing; whereas, once it occurs,
the goal needs to be limiting its progression and reducing the
risk of further adverse cardiovascular events. Attaining good
glycaemic control, by whatever means, is important within
the first 5 years after diagnosis of Type 2 diabetes, and prior
to the onset of micro- or macrovascular disease, because this
decreases the risk of cardiovascular events [5]. However,
prior to 2008, no individual anti-hyperglycaemic agent had
demonstrated a benefit with regard to cardiovascular events
beyond 5 years within a clinical trial setting [5].
As a result of safety concerns raised with the peroxisome
proliferator-activated receptor gamma agonist rosiglitazone
[6], the US Food and Drug Administration (FDA) published a
Guidance for Industry document requiring evidence of the
cardiovascular safety of new anti-hyperglycaemic agents [7].
Since then, data from several cardiovascular outcome trials
of dipeptidyl peptidase-4 inhibitors (DPP-4is) [8–11],
sodium–glucose co-transporter 2 inhibitors (SGLT-2is)
[12–15] and glucagon-like peptide 1 receptor agonists
(GLP-1RAs) [16–22] have been published (Table 1). To
date, all these trials have met their primary endpoint of non-
inferiority compared with placebo with respect to the
composite cardiovascular endpoint of cardiovascular mor-
tality, non-fatal myocardial infarction and stroke [3-point
major adverse cardiovascular events (MACE)] or 4-point
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MACE, including hospitalization for unstable angina
(Table 1). Trials of two SGLT-2is (EMPA-REG [15] with
empagliflozin and CANVAS [12] with canagliflozin) and
three GLP-1RAs (LEADER [20] with liraglutide, HAR-
MONY Outcomes [16] with albiglutide and REWIND [17]
with dulaglutide) have demonstrated the superiority of these
drugs compared with standard of care (including targeted
glycaemic equipoise) for reducing the risk of MACE.
Additionally, a post hoc analysis of the SUSTAIN 6 [22]
trial demonstrated the superiority of the GLP-1RA semaglu-
tide to placebo, and results from DECLARE-TIMI 58
demonstrated that dapagliflozin was non-inferior compared
with placebo with regard to incidence of MACE, but
significantly reduced rates of cardiovascular death and
hospitalization for heart failure [24]. In this review, we
provide an overview of current national and international
guidelines and recommendations for the management of
people with Type 2 diabetes at high risk of cardiovascular
disease, and share our consensus (from an endocrinology,
cardiology and stroke perspective) on clinical recommenda-
tions and decision-making for these people in the UK.
Recent updates to diabetes treatment
guidelines and recommendations
Since publication of EMPA-REG [15], CANVAS [12],
LEADER [20] and SUSTAIN 6 [22], a number of national
and international guidelines and recommendations for the
management of Type 2 diabetes have been updated to
include cardiovascular risk reduction as a key consideration,
and specifically the use of anti-hyperglycaemic agents that
have demonstrated cardiovascular protection in those with
Type 2 diabetes (Table S1). Indeed, some have explicitly
named empagliflozin and liraglutide as appropriate choices
for the management of people with Type 2 diabetes at high
risk for cardiovascular disease [28–47].
Recent updates to international guidelines and
recommendations
Several major international guidelines and recommendations
on the management of Type 2 diabetes specifically cite
EMPA-REG [15], CANVAS [12], LEADER [20] and
SUSTAIN 6 [22], and recommend a hierarchical approach
to drug selection dependent on the strength of this evidence
[3,48–50]. The updated joint American Diabetes Association
(ADA) and European Association for the Study of Diabetes
(EASD) consensus statement emphasizes a stratification of
people based on the presence of pre-existing atherosclerotic
cardiovascular disease before considering which additional
glucose-lowering agent to add as dual therapy (following
metformin failure) [51]. In those with atherosclerotic car-
diovascular disease, the ADA/EASD recommend the use of a
SGLT-2i (with a preference for empagliflozin) for those with
a diagnosis of congestive cardiac failure or chronic kidney
disease, or a GLP-1RA (with a preference for liraglutide or
semaglutide) for those with atherosclerotic disease, as these
agents have been shown to reduce cardiovascular death and
all-cause mortality (except semaglutide) when added to
standard care [51].
Diabetes treatment guidelines in the UK
In 2015, the National Institute for Health and Care Excel-
lence (NICE) of England (also followed in Wales and
Northern Ireland) set up a ‘standing update committee for
diabetes’ to enable faster updates of discrete areas of the
guidelines when new and relevant data are published. Since
then, a number of minor amendments have been made,
including the addition of SGLT-2is to the initial drug
treatment section [52]. However, as yet, no individual
SGLT-2i has been recommended, and there is no mention
of reducing cardiovascular risk in the algorithm. Similarly,
guidelines relating to GLP-1RAs have not yet been updated,
and they remain restricted to settings when triple oral therapy
is not effective, not tolerated or contraindicated, and only if
the person has a BMI ≥ 35 kg/m2 (adjusted accordingly for
ethnic groups), cannot tolerate insulin or weight loss would
benefit other significant obesity-related comorbidities [52].
Moreover, the algorithm has no mention of the use of GLP-
1RAs in people who cannot be treated with metformin.
Consensus treatment recommendations for
people with Type 2 diabetes
Therapy choices based on efficacy
Lifestyle interventions are a key part of Type 2 diabetes
management and should be considered concurrently with
What’s new?
• Following positive cardiovascular outcome trial results,
many national and international guidelines on the
management of people with Type 2 diabetes have been
updated for those also at high risk of cardiovascular
disease. However, not all countries have updated their
guidelines, notably England, Wales and Northern
Ireland.
• This review shares a consensus on clinical recommen-
dations for use of glucagon-like peptide 1 receptor
agonists and sodium–glucose co-transporter 2 inhibi-
tors in people with Type 2 diabetes.
• Although some countries have not yet updated their
guidelines, we recommend consideration of each per-
son’s cardiovascular risk when selecting their diabetes
therapy, to improve long-term outcomes and cost-
effectiveness.
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Table 1 Cardiovascular outcome trials of anti-hyperglycaemic agents
Drug Trial
Cardiovascularoutcome trial
Number
randomized
Treatment
interventions Primary endpoint Primary outcome
DPP-4is
Alogliptin EXAMINE [8]
NCT00968708
5380 25, 12.5 or 6.25 mg OD
(depending on eGFR)
alogliptin vs. placebo
3-point MACE Non-inferiority
demonstrated HR 0.96,
95% CI 1.16*
Linagliptin CAROLINA [9]
NCT01243424
6051 Linagliptin 5 mg OD vs.
glimepiride 1–4 mg OD
4-point MACE (Trial ongoing)
CARMELINA [23]
NCT01897532
6979 Linagliptin OD vs.
placebo
3-point MACE Non-inferiority
demonstrated HR 1.02,
95% CI 0.89 to 1.17
Saxagliptin SAVOR-TIMI-53 [10]
NCT01107886
16 492 5 mg OD (2.5 mg if eGFR
< 50 ml/min)
saxagliptin vs. placebo
3-point MACE Non-inferiority
demonstrated HR 1.00,
95% CI 0.89 to 1.12
Sitagliptin TECOS [11]
NCT00790205
14 671 100 mg OD (50 mg if
eGFR ≥30 to >50 ml/
min 1.73 m2) sitagliptin
vs. placebo
4-point MACE Non-inferiority
demonstrated HR 0.98,
95% CI 0.88 to 1.09
Vildagliptin No ongoing trial n/a n/a n/a n/a
SGLT-2is
Canagliflozin CANVAS [12]
NCT01032629
10 142 100 mg OD canagliflozin
vs. 300 mg OD
canagliflozin vs. placebo
3-point MACE Superiority demonstrated
HR 0.86, 95% CI 0.75
to 0.97
CREDENCE [13]
NCT02065791
4401 100 mg OD canagliflozin
vs. placebo
Composite endpoint of
end-stage kidney
disease, doubling serum
creatinine, and renal or
CV death
Superiority demonstrated
HR 0.70, 95% CI 0.59
to 0.82
Dapagliflozin DECLARE-TIMI 58
[14,24]
NCT01730534
17 160 10 mg OD dapagliflozin
vs. placebo
3-point MACE; also CV
death or hospitalisation
for heart failure
Non-inferiority
demonstrated Upper
boundary of the 95% CI
<1.3; P < 0.001
(Superiority
demonstrated for co-
primary endpoint of CV
mortality and
hospitalisations due to
heart failure [HR 0.83,
95% CI 0.73 to 0.95])
Ertugliflozin VERTIS CV [25]
NCT01986881
8246 5 mg OD ertugliflozin vs.
15 mg OD ertugliflozin
vs. placebo
3-point MACE (Trial ongoing)
Empagliflozin EMPA-REG [15]
NCT01131676
7028 10 or 25 mg
empagliflozin OD vs.
placebo
3-point MACE Superiority demonstrated
HR 0.86, 95% CI 0.74
to 0.99
GLP-1RAs
Albiglutide* HARMONY Outcomes
[16]
NCT01522651
9463 30–50 mg OW albiglutide
vs. placebo
Composite endpoint of
cardiovascular death,
myocardial infarction or
stroke
Superiority demonstrated
HR 0.78, 95% CI 0.68
to 0.90
Dulaglutide REWIND [26]
NCT01394952
9901 1.5 mg OW dulaglutide
vs. placebo
3-point MACE Superiority demonstrated
(press release) HR not
reported
Exenatide EXSCEL [18]
NCT01144338
14 752 2 mg OW exenatide vs.
placebo
Composite endpoint of
cardiovascular death,
non-fatal myocardial
infarction or non-fatal
stroke
Non-inferiority
demonstrated HR 0.91,
95% CI 0.83 to 1.00
ITCA 650 FREEDOM-CVO [19]
NCT01455857
Not reported 60 mcg/day ITCA 650 vs.
placebo
4-point MACE Non-inferiority
demonstrated (press
release) HR not reported
Liraglutide LEADER [20]
NCT01179048
9340 1.8 mg liraglutide OD vs.
placebo
3-point MACE Superiority demonstrated
HR 0.87, 95% CI 0.78
to 0.97
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pharmacotherapy [52]. Unless contraindicated, metformin
remains the mainstay of first-line drug therapy in all people
with Type 2 diabetes. We then recommend assessing cardio-
vascular disease risk to guide further therapy (Fig. 1).
For those with established cardiovascular disease, use of
empagliflozin, canagliflozin, liraglutide or semaglutide is
recommended (based on recent cardiovascular outcome trials
data and in keeping with updated national and international
guidelines; Fig. 1). The specific drug choice may be further
guided by the individual’s cardiovascular history and comor-
bidities. Given their favourable results in reducing hospital-
ization for heart failure, empagliflozin and canagliflozin are a
Table 1 (Continued)
Drug Trial
Cardiovascularoutcome trial
Number
randomized
Treatment
interventions Primary endpoint Primary outcome
Lixisenatide ELIXA [21]
NCT01147250
6068 10 lg (titrated up to
20 lg) OD lixisenatide
vs. placebo
4-point MACE Non-inferiority
demonstrated HR 1.02,
95% CI 0.89 to 1.17
Semaglutide SUSTAIN 6 (pre-
approval) [22]
NCT01720446
3297 (OW injection) 0.5 or
1.0 mg semaglutide vs.
placebo
3-point MACE Non-inferiority
demonstrated HR 0.74,
95% CI 0.58 to 0.95
(superiority
demonstrated post hoc
analysis)
PIONEER 6 (oral
semaglutide) [27]
NCT02692716
3183 Oral semaglutide OD vs.
placebo
3-point MACE Non-inferiority
demonstrated (press
release) HR 0.79
*Upper boundary of the one-sided repeated confidence interval, at an alpha level of 0.01.
†Albiglutide is not currently available in the UK.
BID, twice daily; CI, confidence interval; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; HR,
hazard ratio; MACE, major adverse cardiovascular events; OD, once daily; OW, once weekly; SGLT-2i, sodium-glucose cotransporter-2
inhibitor.
Lifestyle interventions and metformin
Pre-existing or high risk for cardiovascular disease?
eGFR 
≤ 45 ml/min
1.73 m2  or 
atherosclerotic 
cardiovascular 
disease or
stroke
TZDs SUs
Consider person-specific factors including weight 
and hypoglycaemia risk
Low hypoglycaemic risk
Low weight gain
eGFR 
> 45 ml/min
1.73 m2  and
heart failure
SGLT-2is 
empagliflozin 
or 
canagliflozin
GLP-1RAs 
liraglutide or 
semaglutide
GLP-1RAs DPP-4isSGLT-2is
Yes No
FIGURE 1 Initial therapy selection. Order does not denote any specific preference. *Metformin to be continued unless no longer tolerated.
†Individuals are considered a high risk if they have a history of cardiovascular disease or at least one risk factor (see Table S2 for further details).
DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i,
sodium-glucose co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione.
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key consideration for those with heart failure, although the
licences do not allow for initiation if eGFR is < 60 ml/
min 1.73 m2 [12,15,53,54]. Empagliflozin and canagliflozin
should be discontinued when eGFR is persistently below 45
ml/ min 1.73 m2 [53,54].
Significant reductions in MACE were reported with
canagliflozin [12] and empagliflozin [15], and a numerical
reduction with dapagliflozin [24]. However, notably, people
with pre-existing cardiovascular disease should be made
aware of the increased risk of lower leg amputations
associated with canagliflozin [12,54], although no significant
increase was seen in the CREDENCE study [13]. A non-
significant increase in risk of stroke was reported with
empagliflozin despite a reduction in blood pressure [15], and
dapagliflozin should be discussed before treatment in people
with a history of stroke [55].
Liraglutide or semaglutide are recommended for people
with atherosclerotic cardiovascular disease or stroke (or a
cardiovascular risk factor and eGFR ≤ 45 ml/ min 1.73 m2;
Fig. 1), although the use of semaglutide should be cautioned
in those with active diabetic retinopathy, due to an increased
risk of retinopathy events found in SUSTAIN 6 [22,56]. In
LEADER, there was no significant difference in the risk of
diabetic retinopathy associated with liraglutide vs. placebo
[20]. If further treatment intensification is required to achieve
glycaemic control, additional drugs (from another class) with
proven cardiovascular safety are recommended, consistent
with recent international recommendations [51]. Of interest
will be the full results from REWIND, available June 2019,
which evaluated dulaglutide in people with Type 2 diabetes,
69% of whom did not have a prior cardiovascular event at
baseline. In this event-driven study, the press release stated
that dulaglutide significantly reduced the risk of cardiovas-
cular events [17]. Careful consideration of these data (once
published) will be required when considering future guide-
lines to determine whether there was an effect on primary
prevention, or whether the result was driven by the events
occurring predominantly in the 31% with prior cardiovas-
cular disease [17].
For people without confirmed cardiovascular disease,
cardiovascular risk factor modification is still important
(including smoking cessation, hypertension management,
and lipid-lowering and anti-platelet medication). The specific
glucose-lowering drug or drug combination choice is best
guided by individual factors, including consideration of
weight and risk of hypoglycaemia (Fig. 1). Unlike the results
from EMPA-REG for empagliflozin, the DECLARE-TIMI 58
trial did not achieve a reduction in 3-point MACE with
dapagliflozin vs. placebo [24]. This dapagliflozin trial,
however, showed a significant reduction in the co-primary
outcome of cardiovascular mortality and hospitalizations
due to heart failure, which were numerically similar in those
with established disease and in the primary prevention
population. Therefore, dapagliflozin may be considered for
those without established cardiovascular disease but who are
at high risk for heart failure with an eGFR ≥ 60 ml/
min 1.73 m2.
Of note, the mean eGFR of participants in DECLARE-
TIMI 58 (85.2 ml/min 1.73 m2) [24], was higher than in
EMPA-REG (74.1 ml/min 1.73 m2) [15] and CANVAS
(76.5 ml/min 1.73 m2) [12]. This differential in renal func-
tion and the observed differences in cardiovascular and
mortality outcomes raise important questions around the
mechanism of action of these drugs, in terms of cardiovas-
cular effects as well as their optimal therapeutic positioning.
Furthermore, the results of the CREDENCE study, which
evaluated the renovascular outcomes associated with cana-
gliflozin in people with Type 2 diabetes and chronic kidney
disease, also require careful consideration. The study was
discontinued early due to efficacy and outcome benefits in
favour of canagliflozin, and future guidelines therefore need
to take the trial results into consideration [13].
Therapy choices based on cost-effectiveness analyses
Cost-effectiveness analyses may be an additional considera-
tion when choosing therapy. Assessments by NICE show that
most SGLT-2is and GLP-1RAs are cost-effective at reducing
hyperglycaemia with incremental cost-effectiveness ratios
(ICERs) below the commonly accepted £20 000–30 000/
quality-adjusted life-year (QALY) threshold (Table 2). An
early analysis concluded that liraglutide 1.2 mg was cost-
effective but there was uncertainty regarding the 1.8 mg dose
[61]; however, this has been superseded by new analyses in
health technology assessments conducted as part of the NICE
Type 2 diabetes clinical guidelines published in 2015 (and
updated in 2017) [52], which make positive recommenda-
tions for GLP-1RAs as a drug class.
Empagliflozin and canagliflozin have both demonstrated
cost-effectiveness vs. comparators in the UK [62–64]. Several
studies of liraglutide in the UK have also concluded cost-
effectiveness, despite increased acquisition cost, due to
reduction in diabetes-related complications [65–67]. How-
ever, cost-effectiveness analyses evaluate drugs as glucose-
lowering entities, and modelling is therefore based on
traditional risk equations [68–71], which do not capture
potential cardiovascular benefits [72]. Further analyses are
now required to ensure that the additional benefit of reducing
cardiovascular events is captured in cost-effectiveness eval-
uations in people with Type 2 diabetes, based on results from
the respective cardiovascular outcome trials, and to incor-
porate these into updated ICER estimates.
The accepted technique for evaluating potential additional
benefits beyond glycaemic control is termed marginal-effects
analysis. This approach incorporates not just the traditional
risk equation of improved glucose management, but also a
fixed effect for reduction in cardiovascular events by imple-
menting treatment strategies based around empagliflozin,
canagliflozin, liraglutide or semaglutide in populations
reflected by the study data. Evaluation of how the observed
ª 2019 The Authors.
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event rate reductions in the respective trials affect healthcare
resources and hospital bed occupancy is also necessary. This
may be a more comprehensive way of looking at how
implementing the strategies of cardiovascular outcome trials,
impact on the budget and healthcare system compares with
the more typically employed number-needed-to-treat analy-
sis. These economic analyses will no doubt form the basis of
future NICE technology appraisals and a guideline update.
Meanwhile, we believe National Health Service (NHS)
formularies should consider these international guidance
updates to achieve earlier clinical and economic benefits or
be rapidly responsive when NICE also evaluates these data.
With an ever-growing diabetes and cardiovascular disease
population, it is important make these therapies available
without delaying for NICE updates, where the data are
compelling.
Conclusions
Many people with Type 2 diabetes also have, or are at high
risk of, concomitant cardiovascular disease and control of
cardiovascular events remains a key goal for managing
Table 2 Cost-effectiveness of all sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists assessed by National
Institute for Health and Care Excellence
Drug Most likely cost-effectiveness estimate (as an ICER)
SGLT-2is
Canagliflozin The committee concluded that the minor differences in costs and QALYs between canagliflozin (100 and 300 mg) and its
key comparators showed that canagliflozin was a cost-effective use of NHS resources as dual therapy in combination with
metformin, triple therapy in combination with metformin and either a sulphonylurea or a thiazolidinedione, and as an
add-on treatment to insulin [57].
Dapagliflozin  For dapagliflozin as dual therapy in combination with metformin, the committee considered the DSU deterministic
analysis and scenario analyses, which included convergence of differences in weight between treatment groups at the
time of switching to the last line of treatment. It noted that these showed that DPP-4is were associated with higher costs
and QALYs than dapagliflozin, but that these differences were small. It noted further that, in the DSU probabilistic
sensitivity analysis, these differences were even smaller.
 For dapagliflozin as an add-on to insulin, the committee noted that, in all of the analyses conducted by the DSU, the
estimate of the ICER for dapagliflozin, compared with DPP-4is, was below £20 000 per QALY [58].
Ertugliflozin ICER not yet available.
Empagliflozin The committee concluded that the minor differences in costs and QALYs between empagliflozin (10 and 25 mg) and its key
comparators showed that empagliflozin was a cost-effective use of NHS resources as dual therapy in combination with
metformin, triple therapy in combination with metformin and either a sulphonylurea or a thiazolidinedione, and as an
add-on treatment to insulin [59].
GLP-1RAs
Dulaglutide ICER not yet available.
Exenatide The committee noted that the ICERs presented in the manufacturer’s submission were not specific to the place of weekly
prolonged-release exenatide in triple- and dual-therapy regimens. The committee did, however, consider on the basis of
the ICERs presented in the manufacturer’s submission, that weekly prolonged-release exenatide is likely to be cost-
effective when used in the same place in the treatment pathway as twice-daily exenatide and liraglutide 1.2 mg were
currently recommended [60].
Liraglutide  There were many ICERs presented for different comparisons.
 For liraglutide vs. exenatide (triple therapy), the committee accepted the ICER of £10 100 per QALY gained (although
the committee noted that this ICER related to liraglutide 1.8 mg).
 The committee did not consider the ICERs presented for other oral therapies in both dual- and triple-therapy regimens to
be robust enough to allow them to recommend liraglutide as a cost-effective alternative.
 The committee noted the lack of clinical trial evidence showing a significant benefit from increasing the liraglutide dose
from 1.2 to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis. The committee concluded
that liraglutide 1.8 mg would not be a cost-effective use of NHS resources, and therefore was not recommended (NICE
2010[61]; superseded by NG28)[52].
 Note that, although there are no specific references to the cost-effectiveness of liraglutide 1.2 mg, it is recommended for
use in very specific conditions in dual or triple therapy (see: NICE 2010) [52,61].
Lixisenatide ICER not yet available.
Semaglutide ICER not yet available.
DPP-4i, dipeptidyl peptidase-4 inhibitor; DSU, decision support unit; GLP-1RA, glucagon-like peptide-1 receptor agonist; ICER, incremental
cost-effectiveness ratio; NICE, UK National Institute for Health and Care Excellence; NHS, UK National Health Service; NG28, NICE
guideline 28; QALY, quality-adjusted life-year; SGLT-2i, sodium-glucose cotransporter-2 inhibitor.
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outcomes. Given highly favourable results of cardiovascular
outcome trials, many national and international guidelines
and recommendations, including the consensus statement
from the ADA and EASD, have been updated to include these
results and therefore optimize treatment approaches.
Although, in England, Wales and Northern Ireland, NICE
postponed updating recommendations for SGLT-2i and
GLP-1RA classes as some trials are still ongoing, the current
evidence base of these agents has been evaluated by interna-
tional guidelines groups recognizing their benefits. We
therefore recommend evaluating individual’s cardiovascular
risk factors before escalating diabetes therapy and consider-
ing anti-hyperglycaemics with proven cardiovascular benefit,
to improve long-term outcomes, and reduce unplanned
health resource use additionally. Formularies wishing to
reduce the burden of care of diabetes should consider these
latest guidelines as soon as possible to enable clinicians to
maximize diabetes treatment.
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